Streicher, Katie,Yao, Yihong,Ranade, Koustubh,Liang, Meina,Vainshtein, Inna,Piper, Edward,May, Richard,Nordenmark, Lars
申请号：
AU2015209124
公开号：
AU2015209124A1
申请日:
2015.01.26
申请国别(地区):
AU
年份:
2016
代理人:
摘要：
The present disclosure relates to the use of DPP4, protein or gene expression levels, as a biomarker for IL-13 mediated diseases or disorders, e.g., asthma, IPF, COPD or atopic dermatitis. Levels of the DPP4 biomarker above or below a predetermined DPP4 threshold level can be used (i) to determine a patient's eligibility for a certain treatment with a IL-13 antagonist, (ii) to determine whether a certain treatment of an IL-13 mediated condition or disorder with a specific IL-13 antagonist should commence, be suspended, or be modified, (iii) to diagnose whether an IL-13 mediated condition or disorder is treatable or not treatable with a specific IL-13 antagonist, (iv) to prognosticate the outcome of treating an IL-13 mediated condition or disorder with a specific IL-13 antagonist. The disclosure further provides assay kits for the detection of DPP4, as well as computer implemented diagnostic methods.
